This review explores the relationship between inflammatory markers and physical frailty, emphasizing their potential for clinical application. As the global population ages, frailty, characterized by reduced physical reserve and increased vulnerability to adverse health outcomes, becomes a critical concern. Chronic inflammation is closely linked to decreased physical function and increased disease risk, and is considered a major contributor to frailty. Several inflammatory markers, such as IL-6, CRP, and TNF-α, have been proposed as potential indicators of frailty. However, the clinical application of these markers remains limited due to a lack of consensus on their diagnostic and prognostic value. The review highlights the complex interplay between inflammation, cellular processes, and aging, and discusses the biological mechanisms underlying frailty. It also examines various frailty assessment tools and the impact of different frailty criteria on the identification of inflammatory markers. While some studies suggest that IL-6, CRP, and TNF-α are consistent biomarkers of frailty, the results are inconsistent, and further research is needed to determine the most reliable markers. The review proposes the use of an inflammatory index score (IIS), which combines IL-6 and TNFR1 levels, as a potential marker for frailty. This index has shown promise in predicting mortality and has good discriminatory power. However, the complexity of inflammatory processes and the need for more comprehensive biomarker panels remain challenges in the field. Future research should focus on developing more accurate and reliable biomarkers, as well as exploring the role of inflammation in the prevention and treatment of frailty. The review concludes that further studies are needed to translate these findings into clinical practice and improve the management of frailty in older adults.This review explores the relationship between inflammatory markers and physical frailty, emphasizing their potential for clinical application. As the global population ages, frailty, characterized by reduced physical reserve and increased vulnerability to adverse health outcomes, becomes a critical concern. Chronic inflammation is closely linked to decreased physical function and increased disease risk, and is considered a major contributor to frailty. Several inflammatory markers, such as IL-6, CRP, and TNF-α, have been proposed as potential indicators of frailty. However, the clinical application of these markers remains limited due to a lack of consensus on their diagnostic and prognostic value. The review highlights the complex interplay between inflammation, cellular processes, and aging, and discusses the biological mechanisms underlying frailty. It also examines various frailty assessment tools and the impact of different frailty criteria on the identification of inflammatory markers. While some studies suggest that IL-6, CRP, and TNF-α are consistent biomarkers of frailty, the results are inconsistent, and further research is needed to determine the most reliable markers. The review proposes the use of an inflammatory index score (IIS), which combines IL-6 and TNFR1 levels, as a potential marker for frailty. This index has shown promise in predicting mortality and has good discriminatory power. However, the complexity of inflammatory processes and the need for more comprehensive biomarker panels remain challenges in the field. Future research should focus on developing more accurate and reliable biomarkers, as well as exploring the role of inflammation in the prevention and treatment of frailty. The review concludes that further studies are needed to translate these findings into clinical practice and improve the management of frailty in older adults.